Kornimate/medical-research-clean huggingface dataset:
virtual reality rehabilitation protocol for sensory-motor rehabilitation after a stoke

Conditions: Stroke

Summary: introduction: stroke is the second leading cause of death in europe. in the case of stroke survival (almost 70%), only 25% of patients recover completely, while the remaining 75% will undergo a rehabilitation phase that varying from months to years. the main consequences of a stroke include motor disability of the upper limbs, which involves a partial or complete inability to move the right or left limb, depending on the damaged hemisphere. furthermore, the motor deficit distorts the proprioception of the body and the embodiment ability of the injured limb. this could be rehabilitated through the paradigm of body illusion that modulates the motor rehabilitation. the present protocol aims to investigate the effectiveness of a virtual reality system for sensorimotor and proprioception upper limb deficit compared to a traditional upper limb rehabilitation program. method: this study has a randomized and controlled design with control and experimental groups, a 1:1 allocation ratio, and 4 measurement times: pre-intervention, immediately after the intervention, and two follow-ups (at 6 and 12 months). the inclusion criteria are: (a) being 18 to 85 years old, both males and females; (b) suffering from ischemic or hemorrhagic stroke; (c) the stroke event must have occurred from two to eighteen months before recruitment; (d) patients must have moderate to severe upper limb motor deficit, and the alteration of sensorimotor and proprioception abilities of the injury upper limb; (e) patients must understand and sign the written consent for enrolment. the rehabilitation last four weeks with three sessions per week at bellaria hospital of bologna (italy). the vr protocol uses two types of technology: immersive and non-immersive, and the control group follow the traditional rehabilitation program. ethics and dissemination: the protocol was accepted by the local ethics committee (asl_bo n. 0115481) and the clinical trial was promoted.

randomized control trial with active groups.

Eligibility criteria:
inclusion criteria: * being 18 to 85 years old (both male and female) * suffering from ischemic or hemorrhagic stroke * time since the stroke from 2 to 18 months before recruitment * severe upper limb motor deficit established by a score of ≤ 80 on the motricity index * alteration of sensorimotor and proprioception abilities of the injury upper limb (failure in 3 proofs up to 4 of the thumb location test) * understand and sign the written consent for enrolment exclusion criteria: * severe cognitive and behavioral disorders or a state of confusion defined by temporal and/or spatial disorientation detected during an ordinary conversation (evaluate through 4at) * severe upper limb motor deficit (score motricity index scale: gripper \<11, elbow flexion \<14, shoulder abduction \<14) * verbal comprehension ability (score \<2 at token test) * severe spatial neglect ( score of \>3 at barrage test)
measurement of lung water by transpulmonary thermodilution in lung transplanted patients

Conditions: Mucoviscidosis; Pulmonary Insufficiency

Summary: repeated measurements of lung water by single transpulmonary thermodilution during the first postoperative days following lung transplantation


Eligibility criteria:
inclusion criteria: * double-lung transplanted patients exclusion criteria: * none
contribution of l-tyrosine to human decision making in stressful situations

Conditions: Stress, Psychological

Summary: l-tyrosine is a chemical precursor of dopamine. under specific conditions, tyrosine administration can increase brain dopamine levels and therefore several studies have explored whether tyrosine supplementation can have a beneficial effect on cognitive and behavioural performance that is dependent on dopaminergic function. however, the effects of tyrosine supplementation are mixed: some studies show positive effects while others do not. stress leads to an increase in dopaminergic activity and turnover in the brain, resulting in a decrease in brain dopamine levels. we propose to study the contribution of tyrosine to decision making and more particularly to the processes of response selection (mediated by the prefrontal cortex and under the influence of the dopaminergic system) in stressful situations.


Eligibility criteria:
inclusion criteria: * from 18 to 65 years of age exclusion criteria: * tyrosine intake within the previous 15 days * history of neurological or psychiatric disorder * history of nephrological or endocrine disorder or liver failure * hereditary tyrosinemia

Keywords: l-tyrosine
phase 1 study of pazopanib with gsk1120212 in advanced solid tumors, enriched with patients with differentiated thyroid cancer, soft-tissue sarcoma, and cholangiocarcinoma

Conditions: Solid Tumors; Thyroid Cancer; Soft-tissue Sarcoma; Cholangiocarcinoma

Summary: the purpose of this study is to determine the safety and toxicity of the combination of pazopanib and gsk1120212 in patients with solid tumors and identify the maximum tolerated dose (mtd) of this combination for phase ii study.


Eligibility criteria:
inclusion criteria: * dose escalation cohort for all solid tumors is closed to enrollment. * expansion cohorts: soft-tissue sarcoma, cholangiocarcinoma, and differentiated thyroid cancer (dtc) cohorts are closed to enrollment. patients in the dtc cohort must have disease that is able to be biopsied. * must have measurable disease. * tumor progression in the 6-month period prior to study drug initiation. * dtc patients: must have radioiodine non-avid lesions, or radioiodine avid lesions that have not responded to treatment with radioactive iodine. * ecog performance status less than or equal to 1. * life expectancy \>3 months. * blood pressure \<140 mmhg and \<90 mmhg. * lvef is \>= 50% * must be able to swallow pills. exclusion criteria: * chemotherapy, radiotherapy, other investigational therapy, or major surgery within 4 weeks. * sarcoma and cholangiocarcinoma only: prior vegf-targeted tki therapy. * pregnant or currently breastfeeding. * unresolved toxicity greater than grade 1. * evidence of active hepatitis or hiv. * significant cardiovascular disease. * taking medications known to be strong inducers or inhibitors of cyp3a enzymes. * clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding. * history of gastrointestinal condition causing malabsorption or obstruction. * cerebrovascular accident including transient ischemic attack (tia), pulmonary embolism or untreated deep vein thrombosis (dvt) within past 6 months. * known endobronchial lesions and/or lesions infiltrating major pulmonary vessels that increase risk of pulmonary hemorrhage. * hemoptysis within 6 months of starting treatment. * history of retinal vein occlusion (rvo) or central serous retinopathy (csr), or predisposing factors to rvo or csr as assessed by ophthalmic exam. * known brain mets that are not stable for at least 8 weeks prior to treatment, or patient is on glucocorticoids for brain mets.
the effects of two different ventilation strategies on lung ventilation: an ultrasonographic evaluation.

Conditions: Prostate Cancer

Summary: this study will be performed in robotic assisted laparoscopic radical prostatectomy patients in cerrahpasa medical faculty monoblock operating room. since robot-assisted laparoscopic radical prostatectomy is a surgical procedure which requires long-term mechanical ventilation, excessive trendelenburg position (30-45 °) and pneumoperitoneum; these interventions may lead to respiratory complications such as ventilation difficulty and aeration loss in patients. nowadays, lung ultrasonography has been used in anesthesia practice and intensive care units in order to determine lung aeration loss. in this study, the investigators aimed to compare the possible aeration loss in lung parenchyma during pressure controlled ventilation and volume controlled ventilation which are frequently used in anesthesia practice in patients undergoing robotic radical prostatectomy.


Eligibility criteria:
inclusion criteria: 18-75 age * patient who will be undergo robot assisted laparoscopic prostatectomy surgery * patient with asa (american society of anesthesiologists) score 1-3 exclusion criteria: * patients with asa score above 3 * patients with obstructive (fev1\<%60) or restrictive pulmonary disease (fvc\<%60) * patients with intrathoracic operation history * heavy smokers (\>25 cigarettes/day)

Keywords: lung ultrasonography mechanical ventilation pressure controlled ventilation volume controlled ventilation
the effects of prophylactic limited palmar fasciectomy on surgical outcomes and scarring

Conditions: Dupuytren Contracture

Summary: research is instrumental for improving medical care and the patient experience. finding new surgical techniques can create better outcomes and minimize recovery time and complications for patients. some patients undergoing trigger finger surgery with a pre-existing dupuytren's cord may develop a thickened surgical scar after surgery, which can cause discomfort, difficulty with moving or using, and other complications in the affected finger(s) or hand. the investigator is investigating a surgical technique to minimize these potential complications and scarring after surgery. subjects are being asked to take part in this research study because they have been diagnosed with trigger finger and pretendinous dupuytren's cord and have decided to undergo surgery rather than try medical treatment.

patients who have surgery for trigger finger with a thickened overlying dupuytren's cord are at risk for complications including but not limited to scarring, adhesions, stiffness, injury to underlying structures such as blood vessels, tendons and nerves, loss of motion, pain, bowstringing, and recurrent triggering or contracture. they have been shown to have higher risk for these complications including a thickened scar response. the cause for this is not fully understood, but it could be because the pretendinous cord was cut and not removed. by cutting and not removing this pretendinous cord, this may cause extra scarring that may lead to a thicker palmar scar that may become symptomatic. this study will investigate a different surgical method for relieving the tension caused by a pretendinous cord and whether it reduces complications and scarring.

Eligibility criteria:
inclusion criteria: * potential candidates for the study will be selected based upon clinical diagnosis of trigger finger with co-existing pretendinous cord. all potential subjects will have either failed non operative treatment or elected surgical treatment. exclusion criteria: * \<18 years of age
mathematical modeling of the hiv transmission risk after initiation of antiretroviral therapy in naïve hiv-infected

Conditions: HIV-1-infection

Summary: the objective of this study is to explore the impact of initiation of art with different regimens in naïve msm (in the setting of acute and chronic hiv-infection) on the probability of transmission of hiv by mathematical modeling.

the hiv epidemic among men who have sex with men (msm) continues to expand in low, middle, and high-income countries. the disproportionate hiv disease burden in msm is explained largely by the high per act and per-partner transmission probability of hiv transmission in receptive anal sex . current strategies are inadequate to control hiv spread among msm; much more vigorous prevention efforts are required, including the early initiation of antiretroviral therapy (art) that has been shown to reduce the rates of sexual transmission of hiv-1 and the adaptation and expanded use of pre-exposure prophylaxis (prep) to prevent the acquisition of hiv-1 infection . initiation of art with regimens based on integrase strand transfer inhibitors (insti) is associated with a faster decline in hiv-rna load than what is observed with regimens based on non-nucleoside transcriptase inhibitors (nnrti), and protease inhibitors (pi). the clinical impact of this finding is unknown although clinical anecdotes suggest that it may it may cause a rapid decline in hiv rna in women presenting with hiv in late pregnancy. the objective of this study is to explore the impact of initiation of art with different regimens in naïve msm (in the setting of acute and chronic hiv-infection) on the probability of transmission of hiv by mathematical modeling.

Eligibility criteria:
inclusion criteria: * naïve hiv-infected msm exclusion criteria: * none
aging, cognition, and hearing evaluation in elders study

Conditions: Hearing Loss

Summary: the investigators will conduct a small pilot study that will randomize \~ 40 70-84 year-old adults with hearing loss to best-practices hearing rehabilitative treatment (hearing assessment, counseling, fitting of amplification devices) versus a successful aging intervention (one-on-one counseling/education sessions on successful aging topics). participants will be followed for 6 months, and outcomes will focus on communication, quality of life, cognition, and other functional surveys. this pilot study is in preparation for a larger planned trial to investigate if hearing loss treatment can reduce cognitive decline and dementia in older adults.


Eligibility criteria:
inclusion criteria * age 70-84 years. * community-dwelling. * fluent english-speaker. * residency. participants must plan to reside in the local area for the study duration (6 months). * audiometric hearing impairment. participants must have adult-onset hearing impairment with a pure tone average (0.5, 1, and 2 khz) in the better-hearing ear of ≥ 30 decibels and \<70 db. * word recognition in quiet score \>60% bilaterally. * mini-mental state exam (mmse) score ≥ 23 for individuals with high-school degree or less; mini-mental state exam (mmse) score ≥ 25 for individuals with some college or more * willingness to participate. participants must be willing and able to consent to participate in the study, be willing to be randomized to either the hearing intervention or to the successful aging intervention, and be willing to follow the study protocol for the duration of the trial. exclusion criteria potential candidates for enrollment who meet one or more of t he following criteria are excluded from participation in the study: * self-reported disability in ≥ 2 or more activities of daily living (adl) * self-reported hearing aid use in the past year (\>5 hours/week). * vision impairment (worse than 20/40 on mn near vision card). * medical contraindication to use of hearing aids (e.g., draining ear). * conductive hearing impairment as determined by a difference in air audiometry and bone audiometry ("air-bone gap") greater than 15 db in 2 or more contiguous frequencies in both ears. * unwilling to wear hearing aids on a regular (i.e., daily or near daily) basis * no participants are excluded based on race or sex
patient-reported experiences and quality of life outcomes in the tb-practecal clinical trial

Conditions: Multidrug Resistant Tuberculosis

Summary: practecal-pro is a sub-study of a tb-practecal clinical trial for multidrug resistant tuberculosis. it evaluates the effectiveness of tb-practecal interventions from the patient perspective in terms of their quality of life, shared decision making and satisfaction with services.

tolerability of drugs for tb is a complex and dynamic course for patients with drug resistance and can be affected by many different factors. a deeper understanding of the perspectives and experience of men and women participating in novel tb treatment trials will add to the understanding of the safety and efficacy of treatment. tb-practecal is a multicentre, open label, phase 2-3 randomised controlled trial evaluating exclusively oral 6 months regimens containing bedaquiline, pretomanid, linezolid +/- moxifloxacin or clofazimine for the treatment of microbiologically confirmed pulmonary m/xdr-tb. it is registered with the clinicaltrials.gov with identifier number nct02589782. the trial aims to recruit 630 adults from two sites in uzbekistan (nukus and tashkent) and one site each from belarus and south africa. the tb-practecal trial assumes that even if the investigational arms would have non-inferior efficacy and safety compared to the standard of care outcomes, patients would prefer a shorter, exclusively oral regimen with a lower pill count. this study therefore aims to describe patient experiences (i.e. the quality of the treatment experience as opposed to the quantity of treatment or the amount of time spent on it). the practecal-pro sub-study aims to answer the question: "what are the perceptions, expectations and experiences of novel tb treatment for adult patients participating in a six-month regimen clinical trial in uzbekistan, south africa and belarus?" the objectives for the analysis are: * to compare baseline scores between trial patients (all interventional arm patients plus standard of care patients) with healthy controls. * to assess changes in scores over time in patients on the intervention arms and patients on the standard of care arm. * to assess the utility of the sf 12 and sgrq in a tb clinical trial.

Eligibility criteria:
inclusion criteria: * patients recruited into the tb-practecal trial in the approved sites or * local healthy-controls of a similar profile in terms of age and gender aged ≥18 years and * literate in the study questionnaire languages * able to sign the sub-study informed consent form after agreeing to the additional interviews and completion of questionnaires. exclusion criteria: * tb patients excluded from tb-practecal clinical trial * healthy volenteers with co-morbidities * healthy volenteers found to have tb

Keywords: quality of life, drug-resistant tuberculosis
study to investigate the safety, tolerability, and pharmacokinetic profile with oral ab521 in healthy volunteers

Conditions: Healthy Participants

Summary: this study will evaluate the safety and tolerability, pharmacokinetic, and pharmacodynamic profile, and drug-drug interaction (ddi) of casdatifan in healthy participants.


Eligibility criteria:
inclusion criteria: * participants who are healthy volunteers (in the opinion of the investigator) as determined by pre-study medical history, physical examination, vital signs, and 12-lead electrocardiogram (ecg) * all clinical laboratory tests of blood and urine must be within the normal range or show no clinically relevant excursions from the normal range as judged by principal investigator at screening and admission. * screening and randomization hemoglobin ≥for males and females is as follows: * sad: male and female hemoglobin level ≥ 12.5 grams/ deciliters (g/dl) (7.7 millimoles/liters \[mmol/l\]) * mad and ddi: male hemoglobin level ≥ 14.2 g/dl (8.8 mmol/l) and female hemoglobin level ≥ 12.5 g/dl (7.7 mmol/l). * participants should have adequate peripheral venous access. * body weight of 45 kilograms (kg) or greater and body mass index within the range of 18 to 32 kg/meters squared (m\^2) (inclusive) * male participants must be vasectomized and have been vasectomized for at least 3 months prior to screening visit with confirmed history of azoospermia subsequent to the vasectomy procedure * contraceptive use should be consistent with local regulations exclusion criteria: * has any (acute or chronic \[including severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection\]) medical or psychiatric condition that, in the opinion of the investigator, could jeopardize or would compromise the study participant's ability to participate in this study * has history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, cerebrovascular, neurological, or other major disorders capable of significantly altering the absorption, metabolism, or elimination of investigational drug; constituting a risk when taking the study intervention; or interfering with the interpretation of data in the opinion of the investigator * abnormal blood pressure (bp) or pulse measurements at the screening visit or day -2/-1 (admission) in a supine position after 5 minutes of rest as follows: mean systolic bp ≥139 millimeters of mercury (mm hg) or mean diastolic bp ≥89 mm hg; mean pulse \ 100 bpm. * liver enzyme test results: alanine aminotransferase, aspartate aminotransferase, bilirubin, or alkaline phosphatase \>1.0x the upper limit of normal * current or chronic history of liver disease or known hepatic or biliary abnormalities * has 12-lead electrocardiogram with changes considered to be clinically significant at the screening visit or day of admission

Keywords: ab521 hif-2α hypoxia-inducible factor 2 alpha single ascending dose (sad) multiple ascending dose (mad) drug-drug interaction (ddi) casdatifan
genetics of rolandic epilepsy

Conditions: Epilepsy

Summary: the purpose of this study is to find the genes that cause rolandic epilepsy and its related traits.

rolandic epilepsy (re) is the most common type of childhood epilepsy-affecting more than 50,000 children in the united states-and has a complex genetic inheritance. the seizure prognosis is relatively benign, however, many children with re also have problems with speech and language, reading, and motor coordination. symptoms of the disorder overlap with more severe types of epilepsy. the purpose of this study is to find the genes that influence re and its related traits. identifying genetic causes for the variants would improve diagnosis and allow for early intervention. researchers will enroll 1000 children with re and 3000 controls for participation in the study. the scientists will request medical histories and (salivary) dna samples from the participants. participation can be completed by mail and telephone. results from this study should provide important information regarding diagnosis and prognosis of re, may be useful in clinical management, and, eventually, may lead to a cure for this and other forms of epilepsy.

Eligibility criteria:
inclusion: * typical history of focal seizures * eeg centrotemporal sharp waves * age of onset 3-12 years * no previous epilepsy type (febrile seizures ok) * normal development * normal neurological examination * normal mri/ct (if done) exclusion: * only history of secondary generalized seizures * atypical history/semiology * history and eeg inconsistent * abnormal eeg background * very early (\ 12yrs) onset * global neurodevelopmental deficit * deviant neurodevelopment * structural imaging abnormality

Keywords: epilepsy rolandic epilepsy